EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

B King iD, P Mirmirani, K Lo Sicco iD, Y Ramot, R Sinclair iD, L Asfour, K Ezzedine iD, C Paul, M Ohyama, R A Edwards, G Bonfanti, U Kerkmann und 4 weitere

Journal of the European Academy of Dermatology and Venereology · 2025-06 · 39 (6) · 1163-1173

DOI: 10.1111/jdv.20547 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 17.02.2025. Verfasst von B King und 15 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Protein Kinase Inhibitors. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study.

Objectives

This post hoc analysis evaluated individual Severity of Alopecia Tool (SALT) score trajectories in patients who received ritlecitinib 50 mg and rolled over from Phase 2b/3 into the ongoing, open‐label, Phase 3 ALLEGRO‐LT study to describe long‐term response patterns and associated baseline disease characteristics.

Methods

Patients aged ≥12 years with ≥50% scalp hair loss received ritlecitinib 50 mg once daily in both studies. SALT score trajectories from baseline to Month 24 were used to categorise patients as early (SALT score ≤20 at Week 24 and Months 12 and 24), middle (≤20 at Months 12 and 24) or late responders (≤20 by Month 24) or as partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement) or non‐responders (did not achieve 30% improvement). The proportions of patients achieving sustained response (achieved and maintained SALT score ≤20 at all subsequent available time points through Month 24) and complete response (SALT score 0 at ≥1 time point through Month 24) were evaluated. Multivariable logistic regression assessed variables associated with response.

Results

Of 191 patients treated with ritlecitinib 50 mg, 87 (45.5%) were responders (SALT score ≤20), 24 (12.6%) were partial responders, 24 (12.6%) were relapsers and 56 (29.3%) were non‐responders. Of 87 patients categorised as responders, 81 (93.1%) sustained their clinical response and 47 (46.0%) achieved complete response. Factors associated with treatment response included female sex and less extensive and shorter duration of hair loss.

Conclusions

Approximately 45% of patients were SALT score responders, with up to 11% requiring >1 year of ritlecitinib treatment to achieve response, highlighting the importance of extended treatment duration. ClinicalTrials.gov Registration ALLEGRO phase 2b/3 study (NCT03732807); ALLEGRO‐LT study (NCT04006457).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataProtein Kinase InhibitorsAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultTreatment OutcomePyrimidinesPyrroles

Substanzen

PF-06651600Protein Kinase InhibitorsPyrimidinesPyrroles

Autor:innen und Institutionen

  • Dermatology Physicians of Connecticut, Fairfield, Connecticut, USA.
  • The Permanente Medical Group, Vallejo, California, USA.
  • The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, New York, USA.
  • Department of Dermatology, Hadassah Medical Center, Jerusalem, Israel.
  • The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
  • Sinclair Dermatology, Melbourne, Victoria, Australia.

ORCID-Profile: B King, K Lo Sicco, R Sinclair, K Ezzedine

Förderung

  • Pfizer

Zitieren

APA

King, B., Mirmirani, P., Lo Sicco, K., Ramot, Y., Sinclair, R., Asfour, L., Ezzedine, K., Paul, C., Ohyama, M., Edwards, R. A., Bonfanti, G., Kerkmann, U., Wajsbrot, D., Ishowo-Adejumo, R., Zwillich, S. H., & Lejeune, A. (2025). Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. Journal of the European Academy of Dermatology and Venereology, 39(6), 1163-1173. https://doi.org/10.1111/jdv.20547

Vancouver

King B, Mirmirani P, Lo Sicco K, Ramot Y, Sinclair R, Asfour L, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. Journal of the European Academy of Dermatology and Venereology. 2025;39(6):1163-1173. doi:10.1111/jdv.20547

BibTeX
@article{King2025,
  author = {King, B and Mirmirani, P and Lo Sicco, K and Ramot, Y and Sinclair, R and Asfour, L and Ezzedine, K and Paul, C and Ohyama, M and Edwards, R A and Bonfanti, G and Kerkmann, U and Wajsbrot, D and Ishowo-Adejumo, R and Zwillich, S H and Lejeune, A},
  title = {Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  volume = {39},
  number = {6},
  pages = {1163--1173},
  doi = {10.1111/jdv.20547}
}
Kostenlos starten →